

2016-2020 New Frontiers in the UK Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape

<https://marketpublishers.com/r/2414F38317BEN.html>

Date: March 2016

Pages: 565

Price: US\$ 5,440.00 (Single User License)

ID: 2414F38317BEN

Abstracts

Complete report \$6,800. DataPack (test volumes, sales forecasts, supplier shares) \$4,350.

VPGMarketResearchs new report is a study of the major business opportunities emerging in the UK cancer diagnostics market during the next five years. The report examines trends in the UK cancer diagnostics markets, reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

UK Market Overview

Five-year test volume and sales projections.

Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers.

Estimated universe of laboratories performing cancer diagnostic testing.

Cancer statistics, etiology and recent developments.

Business Opportunities and Strategic Recommendations

Specific new product development opportunities with potentially significant market appeal during the next five years.

Design criteria for new products.

Alternative market penetration strategies.

Potential market entry barriers and risks.

Over 200 Current and Emerging Cancer Diagnostic Test

Biochemical Markers

Oncogenes

Growth Factors

Hormones

Colony Stimulating Factors

Lymphokines

Immunohistochemical Stains, and others.

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27, 29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen

Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Supplier Shares, Sales and Volume Forecasts

Sales and market shares of major cancer diagnostic product suppliers by individual test.

Five-year test volume and sales forecasts for major tumor markers by market segment, including:

Hospitals

Commercial/Private Laboratories

Instrumentation Review

Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.

Technology Assessment

Assessment of latest molecular diagnostic methods, biochips/microarrays, biosensors, monoclonal antibodies, immunoassays, chromosome analysis, IT, artificial intelligence, flow cytometry, and other technologies and their potential applications for cancer diagnostic testing.

Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.

Extensive listings of companies, universities and research centers developing

new cancer diagnostic tests and detection technologies.

Competitive Strategies

Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

The companies analyzed in the report include:

Abbott

AdnaGen

Agilent Technologies

Applied Gene Technologies

Arca Biopharma

Beckman Coulter/Danaher

Becton Dickinson

Biomedical Diagnostics

bioMerieux

Bio-Rad

CellSearch

Cepheid

Correlogic Systems/Vermillion

Decode Genetics

Diadexus

Diagnocure

DiaSorin

Eiken Chemical

Elitech Group

Enterix

Enzo Biochem

Epigenomics

Exact Sciences

Fujirebio

Guided Therapeutics

Hologic/Gen-Probe

Kreatech/Leica

Kyowa Medex

Mackay Life Sciences

Myriad Genetics

OncoLab

Ortho-Clinical Diagnostics

Panacea Pharmaceuticals

Polartech

Polymedco

PreMD

Qiagen

Quest Diagnostics

Radiant Pharmaceuticals

Roche

Scienion

Sequenom

Siemens Healthcare

Takara Bio

Targeted Diagnostics & Therapeutics

Thermo Fisher

Tosoh

Veridex

Wako Pure Chemicals

Wallac/PE

Zilla

Contains 565 pages and 85 tables

Contents

I. INTRODUCTION

II. Major Product Development Opportunities

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- D. Auxiliary Products

III. Design Criteria for Decentralized Testing Products

IV. Alternative Market Penetration Strategies

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies
 - 1. MARKETING APPROACHES
 - 2. PRODUCT COMPLEXITY
 - 3. CUSTOMER PREFERENCE
 - 4. ESTABLISHED SUPPLIERS
 - 5. EMERGING SUPPLIERS
 - 6. MAJOR TYPES OF DISTRIBUTORS
 - 7. MARKET SEGMENTATION FACTOR

V. Potential Market Entry Barriers and Risks

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

VI. Worldwide Market and Technology Overview

A. Cancer Statistics and Etiology

1. BREAST CANCER
2. LUNG CANCER
3. COLON AND RECTUM CANCER
4. PROSTATE CANCER
5. STOMACH CANCER
6. LEUKEMIA
7. LYMPHOMA
8. ORAL CANCER
9. SKIN CANCER
10. UTERINE CANCER
11. OVARIAN CANCER
12. BLADDER CANCER

B. Major Current And Emerging Cancer Diagnostic Tests

1. INTRODUCTION
2. TUMOR MARKER CLASSIFICATION
3. ACTH
4. ALPHA-FETOPROTEIN (AFP)
5. BETA-2 MICROGLOBULIN
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. CALCITONIN
10. CARCINOEMBRIONIC ANTIGEN (CEA)
11. ESTROGEN AND PROGESTERONE RECEPTORS
12. FERRITIN
13. GASTRIN
14. HUMAN CHORIONIC GONADOTROPIN (HCG)
15. INSULIN
16. NSE
17. OCCULT BLOOD
18. PAP SMEAR/HPV
19. PROSTATIC ACID PHOSPHATASE (PAP)
20. PROSTATE-SPECIFIC ANTIGEN (PSA)
21. SQUAMOUS CELL CARCINOMA ANTIGEN (SCC)
22. T AND B LYMPHOCYTES
23. TDT
24. THYROGLOBULIN
25. TISSUE POLYPEPTIDE ANTIGEN (TPA)

26. BIOCHEMICAL TUMOR MARKERS

ADA

B-Protein

PNP

5'-Nucleotidase

27. ONCOGENES

Abl/abl-bcr

AIB1

BCL-2

BRCA1

CD44

C-fos

C-myb

C-myc

CYP-17

Erb-B

HPC1

N-myc

P40

P51

P53

PIK3CA

PTI-1

Ras

Reg

Sis

Src

28. POLYPEPTIDE GROWTH FACTORS

Basic Fibroblast Growth Factor

Beta-TGF

Cachectin (TNT)

Calmodulin

ECFR

Nerve Growth Factor (NGF)

Epidermal Growth Factor (EGF)

Ornithine Decarboxylase

Transferrin

Transforming Growth Factor-Alpha

29. ECTOPIC HORMONES

30. COLONY STIMULATING FACTORS**31. LYMPHOKINES**

Alpha-Interferon

B Cell Growth Factors

B Cell Growth Factor (BCGF)

Gamma-Interferon

Interleukin-1 (IL-1)

Macrophage Activating Factor

32. IMMUNOHISTOCHEMICAL STAINS**33. EMERGING TUMOR MARKERS**

N-Acetylglucosamine

Actin

Alpha-Actin

Antineuronal Antibodies

7B2

B72.3

Bax

BCD-F9

BLCA-4

Blood Group Antigens A,B,H

CA 50

CA 72-4/TAG-72

CA 195

CA-242

CA-549

CAM 26

CAR-3

Cathepsin-D

Chromogranin A and B

Cluster 1 Antigen

Cluster-5/5A Antigen

CTA

CU18

DR-70

DU-PAN-2

Endometrial Bleeding Associated Factor

Endostatin

Epithelial Membrane Antigen

Feulgen Hydrolysis

Fibronectin
FSH
(1->3)-L-fucosyltransferase
Gastrin-Releasing Peptide (GRP)
GDCFP-15
Glucagon
Glycoamines
H23
Her-2
Human Carcinoma Antigen
HPA
HSP27
Intermediate Filaments
Cytokeratins/CK18/Cyfra 21-1
Desmin
Gliofibrillary Acid Protein
Neurofilaments
Vimentin
KA 93
Kinases
KP16D3
LAI
Leukocyte Common Antigen
Lewis Antigens
Lysophosphatidic Acid (LPA)
Ma 695/Ma 552
MABDF3
MAG
ME1
Minactivin
MN/CA9
MSA
Mucin Cancer Antigen (MCA)
Multiple Tumor Suppressor 1
Myosin
NEA-130
NMP22
OA-519
Opioid Peptides

P-glycoprotein
Pancreatic Oncofetal Antigen (POA)
Placental Lactogen
PR92
Proliferative Index, Ki-67
Px
RB Inactivation/Deletion
Ret
SCCL 175
Selectin
Sialic Acid
Sialyl SSEA-1/SLX
SN10
Somatostatin
TA-90
TABA
Tachykinin
TAG 12
TPS
Troponin
Tubulin
VCAM
VEGF
Villen

C. Instrumentation Review And Market Needs

D. Current and Emerging Technologies

1. MOLECULAR DIAGNOSTICS

- a. Technology Overview
- b. Amplification Methods
- c. Sequencing
- d. Microarrays/Biochips

2. MONOCLONAL AND POLYCLONAL ANTIBODIES

3. IMMUNOASSAYS

- a. Technological Principle
- b. Radioimmunoassay (RIA)
- c. Enzyme Immunoassays (EIA)

Overview

ELISA

Immunofiltration

- Particle-Membrane Capture Immunoassay
- Enzyme Amplification
- d. Fluorescent Immunoassays
- e. Luminescence
 - Chemiluminescence
 - Bioluminescence
- f. Latex Agglutination
- g. Immunoprecipitation
- h. Affinity Chromatographu
- e. Liposome Flow-Injection Immunoassay
- 4. CHROMOSOME ANALYSIS
 - a. Chronic Myelogenous Leukemia (CML)
 - b. Acute Myeloid Leukemia (AML)
 - c. Acute Lymphoblastic Leukemia (ALL)
 - d. Malignant Lymphomas Lymphoid Malignancies
 - e. Chronic Lymphocytic Leukemia (CLL)
 - f. Solid Cancers
 - g. Chromosomal Translocation and Oncogenes
- 5. ARTIFICIAL INTELLIGENCE
- 6. FLOW CYTOMETRY
- 7. TWO DIMENSIONAL GEL ELECTROPHORESIS (2-DGE)
- 8. BIOSENSORS
- 9. COMPETING/COMPLEMENTING TECHNOLOGIES
 - a. CT
 - b. MRI
 - c. NMR
 - d. PET
 - e. Photonics Spectroscopy
- E. Personal Testing

VII. U.K.

- A. Executive Summary
- B. Business Environment
- C. Market Structure
- D. Market Size, Growth and Major Suppliers' Sales And Market Shares

VIII. Competitive Profiles

Abbott
AdnaGen
Agilent Technologies
Applied Gene Technologies
Arca/Nuvelo
Beckman Coulter/Danaher
Becton Dickinson
Biomedical Diagnostics
bioMerieux
Bio-Rad
CellSearch
Cepheid
Correlogic Systems/Vermillion
Decode
Diadexus
Diagnocure
Diasorin
Eiken Chemical
Epigenomics
Enterix
Enzo Biochem
Exact Sciences
Fujirebio/Innogenetics
Guided Therapeutics
Hologic/Gen-Probe
Kreatech
Kyowa Medex
Mackay Life Sciences
Myriad Genetics
Nanogen Elitech
OncoLab
Ortho-Clinical Diagnostics
Panacea Pharmaceuticals
Polartechnics
Polymedco
PreMD
Qiagen/Ipsogen
Quest Diagnostics
Radient Pharmaceuticals

Roche
Scienion
Sequenom
Siemens Healthcare
Takara Bio
Targeted Diagnostics & Therapeutics
Thermo Fisher/Life Technologies
Tosoh
Veridex
Wako Pure Chemicals
Wallac/PE
Zila

IX. Appendix: Major Universities and Research

Centers Developing Cancer Diagnostic
Technology and Applications

List Of Tables

LIST OF TABLES

Tumor Marker Classification

Major Companies Developing or Marketing ACTH Tests

Major Companies Developing or Marketing AFP Tests

Major Companies Developing or Marketing Beta-2 Microglobulin Tests

Major Companies Developing or Marketing CA 15-3/27.29 Tests

Major Companies Developing or Marketing CA 19-9 Tests

Major Companies Developing or Marketing CA 125 Tests

Major Companies Developing or Marketing Calcitonin Tests

Major Companies Developing or Marketing CEA Tests

Major Companies Developing or Marketing Estrogen Receptor Tests

Major Companies Developing or Marketing Progesterone Receptor Tests

Major Companies Developing or Marketing Ferritin Tests

Major Companies Developing or Marketing Gastrin Tests

Major Companies Developing or Marketing HCG Tests

Major Companies Developing or Marketing Insulin Tests

Major Companies Developing or Marketing NSE Tests

Major Companies Developing or Marketing Occult Blood Tests

Major Companies Developing or Marketing PAP Smear/HPV Tests

Major Companies Developing or Marketing PAP Tests

Major Companies Developing or Marketing PSA Tests

Major Companies Developing or Marketing Lymphocyte Subclassification Tests

Biochemical Markers Potential Applications In Cancer Diagnosis

Oncogenes Potential Applications In Cancer Diagnosis

Major Companies Developing or Marketing Oncogene Tests

Growth Factors Potential Applications In Cancer Diagnosis

Colony Stimulating Factors Potential Applications in Cancer Diagnosis

Lymphokines Potential Applications In Cancer Diagnosis

Immunohistochemical Stains Potential Applications in Cancer Diagnosis

EXECUTIVE SUMMARY TABLE: U.K., Total Tumor Marker Test Volume and Sales

Forecast by Market Segment

U.K., Estimated Cancer Death Rates Per 100,000 Population

U.K., Laboratories Performing Tumor Marker Tests by Market Segment

U.K., Hospital Laboratories Performing Tumor Marker Tests by Bed Size

U.K., Commercial/Private Laboratories Performing Tumor Marker Tests by Annual Test Volume

U.K., Total Tumor Marker Testing Volume Forecast by Market Segment
U.K., All Market Segments Major Tumor Marker Test Volume Forecast
U.K., Hospital Laboratories Major Tumor Marker Test Volume Forecast by Test
U.K., Commercial/Private Laboratories Major Tumor Marker Test Volume Forecast
U.K., Total Tumor Marker Sales Forecast by Market Segment
U.K., All Market Segments Major Tumor Marker Sales Forecast by Test
U.K., Hospital Laboratories Major Tumor Marker Sales Forecast by Test
U.K., Commercial/Private Laboratories Major Tumor Marker Sales Forecast by Test
U.K., ACTH Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., AFP Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Beta-2 Microglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., CA 15-3/27.29 Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., CA 19-9 Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., CA-125 Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Calcitonin Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., CEA Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Chromogranin Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Colon-Specific Antigen Test Volume And Diagnostics Sales by Market Segment
U.K., Cytokeratins Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Estrogen Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Ferritin Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Gastrin Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., HCG Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Insulin Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Lymphocyte Subtyping Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., NSE Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Occult Blood Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Oncogenes Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Pancreatic Oncofetal Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., PAP Smear Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Parathyroid Hormone Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Progesterone Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., PAP Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., PSA Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., S-100 Protein Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Serotonin Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Sialic Acid Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., TDT Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Thymidine Kinase Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Thyroglobulin Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., TPA Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Total Tumor Marker Sales and Market Shares Forecast

U.K., CEA Testing Market Diagnostics Sales by Major Supplier

U.K., PSA Testing Market Diagnostics Sales by Major Supplier

I would like to order

Product name: 2016-2020 New Frontiers in the UK Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape

Product link: <https://marketpublishers.com/r/2414F38317BEN.html>

Price: US\$ 5,440.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2414F38317BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

